Mirum CFO exercises PRSUs, sells shares for taxes

Mirum Pharmaceuticals’ Chief Financial Officer Eric Bjerkholt exercised performance-based equity and sold shares mainly to cover taxes.

Accepted by SEC EDGAR 03/17/2026 - 07:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Mirum Pharmaceuticals’ Chief Financial Officer Eric Bjerkholt exercised performance-based equity and sold shares mainly to cover taxes. He converted 13,334 performance restricted stock units into common stock at a conversion price of $0.0000 per unit. On the next trading day, 7,287 common shares were sold at an average price of $91.9779 per share to satisfy tax withholding obligations tied to this vesting. After these transactions, he directly held 49,788 shares of Mirum common stock.

Insider Trade Summary

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider BJERKHOLT ERIC

Role CHIEF FINANCIAL OFFICER

Sold 7,287 shs ($670K)

Approx. gross sale proceeds $670K

Approx. exercise cost $0.00

Type	Security	Shares	Price	Value
Sale	Common Stock	7,287	$91.9779	$670K
Exercise	Performance Restricted Stock Units	13,334	$0.00	$0.00
Exercise	Common Stock	13,334	$0.00	$0.00

Holdings After Transaction: Performance Restricted Stock Units — 6,666 contracts (Direct); Common Stock — 49,788 shares (Direct)

Footnotes (3)

1. F1. Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
2. F2. Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units.
3. F3. The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Mirum Pharmaceuticals (MIRM) report for its CFO?

Mirum’s CFO Eric Bjerkholt exercised 13,334 performance restricted stock units into common stock and sold 7,287 shares. The sale was specifically to cover tax withholding obligations linked to the vesting, leaving him with 49,788 Mirum common shares held directly.

How many Mirum (MIRM) shares did the CFO sell and at what price?

Eric Bjerkholt sold 7,287 shares of Mirum common stock at an average price of $91.9779 per share. According to the filing, these shares were sold to satisfy tax withholding obligations associated with recently vested performance restricted stock units.

What equity awards did the Mirum (MIRM) CFO exercise in this Form 4?

The CFO exercised 13,334 performance restricted stock units, each representing a contingent right to receive one Mirum common share. These units converted into 13,334 common shares at a conversion price of $0.0000, reflecting stock-based compensation rather than a cash purchase.

How many Mirum (MIRM) shares does the CFO hold after these transactions?

Following the reported transactions, Eric Bjerkholt directly holds 49,788 Mirum common shares. This figure reflects the net position after exercising 13,334 performance restricted stock units and selling 7,287 shares to cover tax withholding obligations related to the vesting event.

Were the Mirum (MIRM) CFO’s stock sales part of a tax-related transaction?

Yes. The filing’s footnote states the 7,287 Mirum common shares were sold to cover tax withholding obligations tied to the vesting of performance restricted stock units, indicating a tax-driven disposition rather than a discretionary open-market sale for portfolio rebalancing.

How do the Mirum (MIRM) performance restricted stock units vest for the CFO?

The filing notes that two-thirds of the performance restricted stock units vest on March 15, 2026, and the remaining one-third vest on March 15, 2027. Each vested unit entitles the holder to receive one share of Mirum common stock upon settlement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BJERKHOLT ERIC

(Last) (First) (Middle)

C/O MIRUM PHARMACEUTICALS, INC.

989 E HILLSDALE BLVD., SUITE 300

(Street)

FOSTER CITY CA 94404

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		13,334	A	(1)	57,075	D
Common Stock	03/16/2026		S(2)		7,287	D	$91.9779	49,788	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Restricted Stock Units	(1)	03/15/2026		M			13,334	(3)	(3)	Common Stock	13,334	$0	6,666	D

Explanation of Responses:

1. Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

2. Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units.

3. The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027.

	/s/ Judit Ryvkin, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.